Provexis (NZCA) Stock Price & Analysis
NZCA Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.01
- 52-Week Range
- EUR 0.00 - EUR 0.02
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 24.06M
- Enterprise Value
- EUR 23.79M
- Total Cash (Recent Filing)
- EUR 893.14K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -10.99
- Next Earnings
- Dec 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
A 45.1% year-on-year revenue increase shows stronger commercial scale and demand for the company's offerings. If growth persists, it can broaden the revenue base and provide operating leverage, although current evidence does not yet establish that profitability will follow.
Debt-Free Balance Sheet
No reported debt across all periods limits refinancing pressure and interest-related financial risk. This conservative structure preserves flexibility to direct future resources toward product commercialisation and operations, while reducing vulnerability if losses continue.
Improved Cash Generation
Positive operating cash flow and roughly £180k of free cash flow in 2026 mark a meaningful improvement from negative free cash flow in 2025. Sustained conversion of revenue into cash would strengthen self-funding capacity and reduce reliance on external capital.
Bears Say
Persistent Losses
Continued operating and net losses, alongside a net margin near -40%, show that recent revenue expansion has not translated into viable earnings. Persistent losses can consume resources and make the route to breakeven dependent on material margin improvement.
Declining Equity And Negative ROE
Equity declined from 2025 to 2026 while 2026 ROE was roughly -45%, indicating that shareholder capital is not currently generating returns. Further losses could erode the balance-sheet cushion and reduce flexibility to fund growth without improvement.
Volatile Cash Flow
Cash generation remains unproven: the company has recorded repeated cash burn, and the 2026 free-cash-flow improvement is described as volatile. Without sustained positive cash flow, funding operations and commercial expansion may remain difficult despite the debt-free balance sheet.
NZCA FAQ
What was Provexis’s price range in the past 12 months?
What is Provexis’s market cap?
When is Provexis’s upcoming earnings report date?
How were Provexis’s earnings last quarter?
Is Provexis overvalued?
Does Provexis pay dividends?
What is Provexis’s EPS estimate?
How many shares outstanding does Provexis have?
What happened to Provexis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Provexis?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Provexis
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ian Ford
- Employees
- 2
- Website
- www.provexis.com
- Address
- 2 Blagrave Street, Reading, BR, RG1 1AZ, GB
Provexis (NZCA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 10 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 1 | 0 | 7 |







